

ImmuneID Raises \$17M Financing

Client News February 17, 2021

Gunderson Dettmer represented client ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, in its \$17 million financing led by Longwood Fund.

In the announcement of the transaction, co-founder of ImmuneID Stephen Elledge, Ph.D. said, "High-quality therapeutic target identification has remained a vexing bottleneck in drug discovery. The ImmuneID platform, including the VirScan technology, relieves this bottleneck by using its massively parallel, multiplexed, and unbiased approach to provide previously unavailable insight into human immune responses throughout the course of disease progression."

The Gunderson deal team was led by Tim Ehrlich and included George Pothoulakis, Christopher Sintetos and Blake Rowe.

Related People



the state of the state of

Featured Insights

PUBLIC VENTURES

Trump Executive Order Targets Proxy Advisors Over DEI and ESG Influence

EVENTS

Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAl

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees